Conduit Pharmaceuticals announces new addition to autoimmune pipeline

Conduit Pharmaceuticals (CDT) announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting ... > react

Open the Full Article Open the Full Article - Posted 4 weeks ago

React to this Article

Your Name or Nickname

Your Email (will not be shown)
4 x 2 = ?

The source opens up when you press the "Open The Full Article" link above. Its content doesn't belong to us, we're not responsible for it. If you don't think this content is appropriate, or if you're the owner of the source and do not wish to have your article displayed here, please just contact us.

Latest New York News Reports